ReviewAmerican journal of cancer research2025
Advances and potentials in platelet-circulating tumor cell crosstalk.
Review in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
- The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASHuman cell · 2026Article
- Identification of epithelial, mesenchymal, and platelet-associated circulating tumour cells with translational implications in oral squamous cell carcinoma.Scientific reports · 2026Article
- Hemostasis at the edge between physiology and cancer.Internal and emergency medicine · 2026Review
- Platelet‑circulating tumor cell crosstalk: A pivotal target in cancer diagnosis and therapy (Review).Oncology reports · 2026Review
- Bridging Immunity and Hemostasis: Technical Foundations of Platelet-Leukocyte Co-cultures.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Osteosarcoma pulmonary metastasis: the hemodynamic mechanical-filtration hypothesis for subpleural predominance.Frontiers in oncology · 2026Article
- Breast cancer stem cells and circulating tumor cells: Dual drivers of progression and relapse.World journal of stem cells · 2025Review
- Article
- Systemic immune-inflammation index and lymphocyte-to-monocyte ratio predict recurrence after radical surgery for stage I/II endometrial cancer.American journal of cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor metastasis leads to circulating tumor cells (CTCs) that separate from primary malignant tumors and enter blood circulation. CTCs survive and engage with other cells to cope with obstacles, including shear stress, disease, immune attacks, and drugs. Platelets are the best partners for CTCs. Platelets provide a good protective layer for CTCs to ensure that are not monitored and cleared by the native immune system, and protected from shear stress and survive better. Here, we review current reports on platelet-CTC interaction and the clinical relevance of their combination and summarize new techniques for CTC capture and treatment based on platelet-CTC interaction. We discuss current data, identify its shortcomings, and suggest future developments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.